CAD 1.03
(1.98%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -18.22 Million USD | -47.51% |
2022 | -4.53 Million USD | 43.71% |
2021 | -8.06 Million USD | -638.68% |
2020 | 1.49 Million USD | -74.11% |
2019 | 5.78 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 867.17 Thousand USD | 134.63% |
2024 Q2 | -341.03 Thousand USD | -139.33% |
2023 FY | - USD | -47.51% |
2023 Q2 | -3.4 Million USD | -3030.03% |
2023 Q4 | -2.5 Million USD | -276.28% |
2023 Q3 | -665.4 Thousand USD | 80.45% |
2023 Q1 | -108.75 Thousand USD | -122.51% |
2022 FY | - USD | 43.71% |
2022 Q4 | 483.14 Thousand USD | 151.67% |
2022 Q3 | -935.13 Thousand USD | 46.76% |
2022 Q2 | -1.75 Million USD | 23.97% |
2022 Q1 | -2.31 Million USD | -81.07% |
2021 Q4 | -1.27 Million USD | 76.21% |
2021 Q1 | 43.86 Thousand USD | -95.97% |
2021 Q3 | -5.36 Million USD | -476.68% |
2021 FY | - USD | -638.68% |
2021 Q2 | -929.88 Thousand USD | -2220.13% |
2020 Q3 | -84.68 Thousand USD | -127.99% |
2020 Q2 | 302.58 Thousand USD | 58.82% |
2020 Q1 | 190.51 Thousand USD | -19.1% |
2020 FY | - USD | -74.11% |
2020 Q4 | 1.08 Million USD | 1385.1% |
2019 Q3 | 1.42 Million USD | 0.0% |
2019 Q4 | 235.5 Thousand USD | -83.46% |
2019 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Aequus Pharmaceuticals Inc. | -2.68 Million CAD | -579.829% |
CanadaBis Capital Inc. | 5.67 Million CAD | 421.048% |
Decibel Cannabis Company Inc. | 5.67 Million CAD | 420.986% |
Delivra Health Brands Inc. | 2.35 Million CAD | 874.375% |
Entourage Health Corp. | -21.39 Million CAD | 14.806% |
Lifeist Wellness Inc. | -12.76 Million CAD | -42.749% |
Cannara Biotech Inc. | 17.18 Million CAD | 206.06% |
Medicure Inc. | 1.27 Million CAD | 1531.955% |
PharmaCielo Ltd. | -12.01 Million CAD | -51.671% |
Rubicon Organics Inc. | 1.94 Million CAD | 1035.769% |
BioSyent Inc. | 9.05 Million CAD | 301.254% |
Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | -1392.997% |